OncoMatch/Clinical Trials/NCT06909877
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Is NCT06909877 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies HH2853 Tablets for relapsed/refractory peripheral t-cell lymphoma (r/r ptcl).
Treatment: HH2853 Tablets — This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systematic combination chemotherapy
Patients must have histologically confirmed diagnosis of R/R PTCL who have received at least one line of prior systematic combination chemotherapy and at least one new drug therapy (prior antitumor treatment lines ≤4 lines) : relapse and/or refractory.
Must have received: new drug therapy
at least one new drug therapy (prior antitumor treatment lines ≤4 lines) : relapse and/or refractory.
Cannot have received: EZH2 inhibitor
Previous treatment with EZH2 or EZH1/2 inhibitors
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify